Browsing Breast Cancer Research by title
Now showing items 553-572 of 676
-
Safety and efficacy of T-DM1 in 128 patients with advanced HER2+breast cancer: The Royal Marsden experience
(OXFORD UNIV PRESS, 2019-10-01) -
Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience.
(Elsevier BV, 2020-01-01)BACKGROUND: Ado-trastuzumab emtansine (T-DM1) is standard of care for patients with advanced HER2+ breast cancer who relapse within 6 months of adjuvant trastuzumab or progress on first-line anti-HER2 therapy. We evaluated ... -
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
(ELSEVIER SCI LTD, 2023-09-01)The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become the standard of care for hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, improving ... -
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
(AMER ASSOC CANCER RESEARCH, 2016-05-01)Resistance to available hormone therapies in prostate cancer has been associated with alternative splicing of androgen receptor (AR) and specifically, the expression of truncated and constitutively active AR variant 7 ... -
Selective autophagy controls innate immune response through a TAK1/TAB2/SH3PX1 axis.
(CELL PRESS, 2022-01-25)Selective autophagy is a catabolic route that turns over specific cellular material for degradation by lysosomes, and whose role in the regulation of innate immunity is largely unexplored. Here, we show that the apical ... -
Selective autophagy receptors in pancreatic ductal adenocarcinoma
(Institute of Cancer Research (University Of London), 2022-07-06)Pancreatic cancer accounted for 2.5% of all new cancers diagnosed worldwide in 2018, but remains disproportionally one of the most lethal cancers. Therefore, the development and validation of novel biomarkers (BMs), for ... -
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
(NATURE PORTFOLIO, 2023-08-01)SF3B1 hotspot mutations are associated with a poor prognosis in several tumor types and lead to global disruption of canonical splicing. Through synthetic lethal drug screens, we identify that SF3B1 mutant (SF3B1MUT) cells ... -
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
(WILEY, 2015-03-01)Mutations in genes encoding proteins involved in RNA splicing have been found to occur at relatively high frequencies in several tumour types including myelodysplastic syndromes, chronic lymphocytic leukaemia, uveal melanoma, ... -
Shared heritability and functional enrichment across six solid cancers.
(NATURE PORTFOLIO, 2019-01-25)Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total ... -
Short-term presurgical treatment for all?
(BIOMED CENTRAL LTD, 2007-01-01) -
Signal Integration by the IκB Protein Pickle Shapes Drosophila Innate Host Defense.
(CELL PRESS, 2016-09-14)Pattern recognition receptors are activated following infection and trigger transcriptional programs important for host defense. Tight regulation of NF-κB activation is critical to avoid detrimental and misbalanced responses. ... -
Signalling pathways implicated in early mammary gland morphogenesis and breast cancer.
(PUBLIC LIBRARY SCIENCE, 2006-08-01)Specification of mammary epithelial cell fate occurs during embryogenesis as cells aggregate to form the mammary anlage. Within the embryonic mammary bud, a population of epithelial cells exists that will subsequently ... -
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2017-09-15)Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer that is associated with a poor prognosis. We evaluated the activity of CDK4/6 inhibitors across the TNBC subtypes and investigated ... -
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
(NATURE PORTFOLIO, 2021-11-08)PARP enzymes utilise NAD+ as a co-substrate for their enzymatic activity. Inhibition of PARP1 is synthetic lethal with defects in either BRCA1 or BRCA2. In order to assess whether other genes implicated in NAD+ metabolism ... -
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.
(AMER ASSOC CANCER RESEARCH, 2022-11-02)UNLABELLED: Gastric cancer represents the third leading cause of global cancer mortality and an area of unmet clinical need. Drugs that target the DNA damage response, including ATR inhibitors (ATRi), have been proposed ... -
Smoking and risk of breast cancer in the Generations Study cohort.
(BMC, 2017-11-22)BACKGROUND: Plausible biological reasons exist regarding why smoking could affect breast cancer risk, but epidemiological evidence is inconsistent. METHODS: We used serial questionnaire information from the Generations ... -
SOX11 promotes epithelial/mesenchymal hybrid state and alters tropism of invasive breast cancer cells.
(eLife Sciences Publications, Ltd, 2020-09-10)SOX11 is an embryonic mammary epithelial marker that is normally silenced prior to birth. High SOX11 levels in breast tumours are significantly associated with distant metastasis and poor outcome in breast cancer patients. ... -
SOX11 promotes invasive growth and ductal carcinoma in situ progression.
(WILEY, 2017-10-01)Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions. Mature mammary ... -
Sox11 regulates mammary tumour-initiating and metastatic capacity in Brca1-deficient mouse mammary tumour cells.
(COMPANY BIOLOGISTS LTD, 2021-05-01)Little is known about the role of Sox11 in the regulation of mammary progenitor cells. Sox11 is expressed by mammary bud epithelial cells during embryonic mammary gland development and is not detected in mammary epithelial ...